XAT 2018 Registration

Verastem trades as part of the biotechnology industry and is in the healthcare sector. The company CEO is Robert Forrester. Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.

Previous Intraday Performance:

The VSTM shares had a previous change of -2.90% which opened at 1.35 and closed at 1.38. It moved to an intraday high of 1.40 and a low of 1.31.

SeekingAlpha:  Verastem: A Speculative Buy

Historical Performance:

Over the last five trading days, VSTM shares returned -9.80% and in the past 30 trading days it returned -49.26%. Over three months, it changed -57.93%. In one year it has changed -75.92% and within that year its 52 week high was 10.35 and its 52 week low was 1.20. VSTM stock is 15.00% above its 52 week low.

Our calculations result in a 200 day moving average of 4.70 and a 50 day moving average of 2.43. Right now, VSTM stock is trading -70.62% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Verastem: A Speculative Buy


The company has a market cap of $99.0m with 73.9m shares outstanding and a float of 72.2m shares. Trading volume was 788,364 shares and has experienced an average volume of 2,440,660 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Verastem was -1.38 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.49.

1stQtr 2019 -0.524thQtr 2018 -0.383rdQtr 2018 -0.292ndQtr 2018 -0.301stQtr 2018 -0.41

The growth of the EPS is critical in understanding the current valuation of Verastem.

Indicators Also to Watch:

Based on the latest filings, there is 80.10% of institutional ownership.

The beta was calculated to be 2.98.

SeekingAlpha:  Varonis Systems’ (VRNS) CEO Yaki Faitelson on Q1 2019 Results – Earnings Call Transcript

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -140.91%, return on assets is -57.40%, price-to-sales is 3.88 and price-to-book is 1.24.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here